Esperion Therapeutics, Inc. - ESPR
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | President and CEO | S | D | 25,578.0 | 2.719 | 69,546.58 | 2,172,699.0 | View | |
| Mar 18, 2026 | Chief Legal Officer | S | D | 5,708.0 | 2.703 | 15,428.72 | 679,348.0 | View | |
| Mar 18, 2026 | Chief Financial Officer | S | D | 6,424.0 | 2.705 | 17,376.92 | 713,602.0 | View | |
| Mar 16, 2026 | President and CEO | A | A | 647,460.0 | 0.0 | 0.0 | 647,460.0 | View | |
| Mar 16, 2026 | President and CEO | A | A | 723,760.0 | 0.0 | 0.0 | 2,198,277.0 | View | |
| Mar 16, 2026 | Chief Legal Officer | A | A | 269,230.0 | 0.0 | 0.0 | 269,230.0 | View | |
| Mar 16, 2026 | Chief Legal Officer | A | A | 300,840.0 | 0.0 | 0.0 | 685,056.0 | View | |
| Mar 16, 2026 | Chief Financial Officer | A | A | 221,270.0 | 0.0 | 0.0 | 221,270.0 | View | |
| Mar 16, 2026 | Chief Financial Officer | A | A | 247,430.0 | 0.0 | 0.0 | 720,026.0 | View | |
| Jan 21, 2026 | General Counsel | S | D | 1,689.0 | 2.882 | 4,867.7 | 384,216.0 | View | |
| Dec 18, 2025 | General Counsel | S | D | 6,517.0 | 3.667 | 23,897.84 | 385,905.0 | View | |
| Dec 18, 2025 | Chief Financial Officer | S | D | 7,337.0 | 3.667 | 26,904.78 | 467,525.0 | View | |
| Dec 18, 2025 | President and CEO | S | D | 48,244.0 | 3.673 | 177,200.21 | 1,470,587.0 | View | |
| Dec 08, 2025 | Chief Commercial Officer | A | A | 380,000.0 | 0.0 | 0.0 | 380,000.0 | View | |
| Dec 08, 2025 | Chief Commercial Officer | A | A | 424,536.0 | 0.0 | 0.0 | 424,536.0 | View |